About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Ethics Approval to Commence Topical TPM®/Oxycodone Patch Trial

December 8, 2014

Click here to read more

Post navigation

Phosphagenics Newsletter November 2014

Phosphagenics Appoints Dr Ross Murdoch as Chief Executive Officer

Related Posts

Phosphagenics Provides Update on TPM Propofol Development Program

November 9, 2017

Animal Health Update

May 31, 2021May 31, 2021

Quarterly Shareholder Update

July 1, 2015

Recent Posts

First Patient Dosed in Phase III Insomnia Trial
May 16, 2024
MEDIA | Channel 9 News
March 28, 2024
Avecho’s Phase III Clinical Trial for Insomnia Commences
March 26, 2024

Categories

Analyst Coverage
Company Announcement
Company Report
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.